25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

AB3A (Sarepta) Stock Analysis
Buy, Hold or Sell?

Let's analyze Sarepta together

I guess you are interested in Sarepta Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Sarepta’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Sarepta’s Price Targets

I'm going to help you getting a better view of Sarepta Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Sarepta Therapeutics Inc

I send you an email if I find something interesting about Sarepta Therapeutics Inc.

1. Quick Overview

1.1. Quick analysis of Sarepta (30 sec.)










1.2. What can you expect buying and holding a share of Sarepta? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
€13.84
Expected worth in 1 year
€19.90
How sure are you?
48.5%

+ What do you gain per year?

Total Gains per Share
€6.06
Return On Investment
18.5%

For what price can you sell your share?

Current Price per Share
€32.80
Expected price per share
€0 - €81.78
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Sarepta (5 min.)




Live pricePrice per Share (EOD)
€32.80
Intrinsic Value Per Share
€6.60 - €9.68
Total Value Per Share
€20.45 - €23.52

2.2. Growth of Sarepta (5 min.)




Is Sarepta growing?

Current yearPrevious yearGrowGrow %
How rich?$1.5b$769.2m$427.1m35.7%

How much money is Sarepta making?

Current yearPrevious yearGrowGrow %
Making money$58.7m-$133.9m$192.7m327.8%
Net Profit Margin10.5%-53.5%--

How much money comes from the company's main activities?

2.3. Financial Health of Sarepta (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#47 / 890

Most Revenue
#36 / 890

Most Profit
#37 / 890

Most Efficient
#109 / 890
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Sarepta?

Welcome investor! Sarepta's management wants to use your money to grow the business. In return you get a share of Sarepta.

First you should know what it really means to hold a share of Sarepta. And how you can make/lose money.

Speculation

The Price per Share of Sarepta is €32.80. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Sarepta.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Sarepta, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €13.84. Based on the TTM, the Book Value Change Per Share is €1.51 per quarter. Based on the YOY, the Book Value Change Per Share is €1.07 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Sarepta.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 β‚¬% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share
Usd Eps1.624.9%0.601.8%-1.36-4.2%-0.85-2.6%-1.01-3.1%-0.98-3.0%
Usd Book Value Change Per Share3.129.5%1.705.2%1.213.7%0.511.6%0.361.1%0.471.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share3.129.5%1.705.2%1.213.7%0.511.6%0.361.1%0.471.4%
Usd Price Per Share130.19-138.53-121.19-121.46-116.58-104.45-
Price to Earnings Ratio20.11-207.58--37.62-50.90-15.29--0.15-
Price-to-Total Gains Ratio41.72-99.08-275.23-83.32--1.22--31.82-
Price to Book Ratio8.38-11.80-15.67-16.04-15.34-13.59-
Price-to-Total Gains Ratio41.72-99.08-275.23-83.32--1.22--31.82-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share36.82784
Number of shares27
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share1.700.36
Usd Total Gains Per Share1.700.36
Gains per Quarter (27 shares)45.919.75
Gains per Year (27 shares)183.6238.99
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1018417403929
2036735807868
305515420117107
407347260156146
509189100195185
60110210940234224
70128512780273263
80146914620312302
90165316460351341
100183618300390380

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%5.07.00.041.7%5.015.00.025.0%6.027.00.018.2%6.027.00.018.2%
Book Value Change Per Share4.00.00.0100.0%8.04.00.066.7%10.010.00.050.0%16.017.00.048.5%16.017.00.048.5%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.033.00.0%0.00.033.00.0%
Total Gains per Share4.00.00.0100.0%8.04.00.066.7%10.010.00.050.0%16.017.00.048.5%16.017.00.048.5%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Sarepta Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--2.7791.514+84%1.075+159%0.453+514%0.321+764%0.420+562%
Book Value Per Share--13.84410.845+28%6.973+99%7.751+79%7.487+85%7.294+90%
Current Ratio--4.2013.997+5%4.744-11%4.461-6%5.203-19%6.653-37%
Debt To Asset Ratio--0.6150.666-8%0.755-19%0.742-17%0.737-17%0.579+6%
Debt To Equity Ratio--1.5942.019-21%3.094-48%3.300-52%3.194-50%2.158-26%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--9224379328.80010024511889.000-8%8494887139.000+9%8488628185.000+9%8175744345.776+13%7748836341.182+19%
Eps--1.4410.533+170%-1.214+184%-0.758+153%-0.896+162%-0.877+161%
Ev To Sales Ratio--3.9346.345-38%8.080-51%7.569-48%10.443-62%21.246-81%
Free Cash Flow Per Share--0.489-0.799+263%-1.333+373%-0.980+300%-0.795+262%-0.795+262%
Free Cash Flow To Equity Per Share--0.933-0.516+155%-1.049+212%-0.615+166%-0.012+101%-0.012+101%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--9.678----------
Intrinsic Value_10Y_min--6.602----------
Intrinsic Value_1Y_max---3.215----------
Intrinsic Value_1Y_min---3.161----------
Intrinsic Value_3Y_max---6.471----------
Intrinsic Value_3Y_min---6.242----------
Intrinsic Value_5Y_max---5.881----------
Intrinsic Value_5Y_min---5.733----------
Market Cap3222826188.800-254%11392887091.20012122444544.000-6%10605603712.000+7%10628939724.800+7%10202111768.576+12%9140565106.564+25%
Net Profit Margin--0.2420.105+131%-0.535+321%-0.396+264%-0.558+331%-1.143+573%
Operating Margin----0%-0.1360%-0.2350%-0.4310%-1.0070%
Operating Ratio--0.9551.067-10%1.387-31%1.393-31%1.630-41%1.982-52%
Pb Ratio2.369-254%8.37511.798-29%15.671-47%16.037-48%15.336-45%13.594-38%
Pe Ratio5.689-254%20.112207.576-90%-37.621+287%50.903-60%15.290+32%-0.154+101%
Price Per Share32.800-254%115.950123.375-6%107.938+7%108.175+7%103.831+12%93.027+25%
Price To Free Cash Flow Ratio16.768-254%59.277-66.441+212%-22.389+138%-39.538+167%-32.126+154%-19.470+133%
Price To Total Gains Ratio11.803-254%41.72399.078-58%275.233-85%83.325-50%-1.223+103%-31.820+176%
Quick Ratio--1.1671.878-38%2.712-57%2.252-48%1.759-34%2.433-52%
Return On Assets--0.0400.016+157%-0.044+209%-0.028+171%-0.034+185%-0.049+221%
Return On Equity--0.1040.044+138%-0.189+282%-0.159+253%-0.162+256%-0.144+239%
Total Gains Per Share--2.7791.514+84%1.075+159%0.453+514%0.321+764%0.420+562%
Usd Book Value--1527346498.1511196458680.571+28%769264301.289+99%855116986.657+79%825968667.861+85%804721377.360+90%
Usd Book Value Change Per Share--3.1201.700+84%1.207+159%0.509+514%0.361+764%0.471+562%
Usd Book Value Per Share--15.54412.177+28%7.829+99%8.703+79%8.406+85%8.190+90%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--10357133110.37711255521948.969-8%9538059279.669+9%9531031726.118+9%9179725751.437+13%8700393443.879+19%
Usd Eps--1.6180.598+170%-1.363+184%-0.851+153%-1.006+162%-0.985+161%
Usd Free Cash Flow--53950029.800-88162920.473+263%-147022928.848+373%-108068432.666+300%-87655051.984+262%-53124273.930+198%
Usd Free Cash Flow Per Share--0.549-0.897+263%-1.496+373%-1.100+300%-0.892+262%-0.892+262%
Usd Free Cash Flow To Equity Per Share--1.048-0.580+155%-1.178+212%-0.691+166%-0.014+101%-0.014+101%
Usd Market Cap3618589244.785-254%12791933625.99913611080734.003-6%11907971847.834+7%11934173523.005+7%11454931093.757+12%10263026501.650+25%
Usd Price Per Share36.828-254%130.189138.525-6%121.192+7%121.459+7%116.581+12%104.451+25%
Usd Profit--159007825.39558794525.332+170%-133959561.569+184%-83663835.498+153%-98831107.978+162%-96740615.971+161%
Usd Revenue--658241550.301475371653.919+38%310753531.294+112%339772683.537+94%265946833.856+148%186684567.675+253%
Usd Total Gains Per Share--3.1201.700+84%1.207+159%0.509+514%0.361+764%0.471+562%
 EOD+4 -4MRQTTM+26 -9YOY+28 -73Y+29 -65Y+29 -610Y+28 -7

3.3 Fundamental Score

Let's check the fundamental score of Sarepta Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-155.689
Price to Book Ratio (EOD)Between0-12.369
Net Profit Margin (MRQ)Greater than00.242
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.167
Current Ratio (MRQ)Greater than14.201
Debt to Asset Ratio (MRQ)Less than10.615
Debt to Equity Ratio (MRQ)Less than11.594
Return on Equity (MRQ)Greater than0.150.104
Return on Assets (MRQ)Greater than0.050.040
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of Sarepta Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5024.918
Ma 20Greater thanMa 5048.069
Ma 50Greater thanMa 10068.140
Ma 100Greater thanMa 20090.752
OpenGreater thanClose33.200
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About Sarepta Therapeutics Inc

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients with Duchenne with a confirmed mutation in the Duchenne gene. The company is also developing SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Catalent Maryland, Inc.; Nationwide Children's Hospital; Dyno Therapeutics; Hansa Biopharma; Duke University; and Genethon. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Fundamental data was last updated by Penke on 2025-05-01 17:49:06.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just not able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Sarepta earns for each €1 of revenue.

  • Above 10% is considered healthy but always compareΒ Sarepta to theΒ Biotechnology industry mean.
  • A Net Profit Margin of 24.2%Β means thatΒ €0.24 for each €1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Sarepta Therapeutics Inc:

  • The MRQ is 24.2%. The company is making a huge profit. +2
  • The TTM is 10.5%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ24.2%TTM10.5%+13.7%
TTM10.5%YOY-53.5%+63.9%
TTM10.5%5Y-55.8%+66.3%
5Y-55.8%10Y-114.3%+58.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ24.2%-91.8%+116.0%
TTM10.5%-183.9%+194.4%
YOY-53.5%-195.7%+142.2%
3Y-39.6%-245.0%+205.4%
5Y-55.8%-351.3%+295.5%
10Y-114.3%-492.7%+378.4%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Sarepta is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Sarepta to theΒ Biotechnology industry mean.
  • 4.0% Return on Assets means thatΒ Sarepta generatedΒ €0.04 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Sarepta Therapeutics Inc:

  • The MRQ is 4.0%. Using its assets, the company is less efficient in making profit.
  • The TTM is 1.6%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ4.0%TTM1.6%+2.4%
TTM1.6%YOY-4.4%+6.0%
TTM1.6%5Y-3.4%+5.0%
5Y-3.4%10Y-4.9%+1.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.0%-11.3%+15.3%
TTM1.6%-11.5%+13.1%
YOY-4.4%-11.5%+7.1%
3Y-2.8%-11.9%+9.1%
5Y-3.4%-12.5%+9.1%
10Y-4.9%-14.2%+9.3%
4.3.1.3. Return on Equity

Shows how efficient Sarepta is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Sarepta to theΒ Biotechnology industry mean.
  • 10.4% Return on Equity means Sarepta generated €0.10Β for eachΒ €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Sarepta Therapeutics Inc:

  • The MRQ is 10.4%. Using its investors money, the company is less efficient in making profit.
  • The TTM is 4.4%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ10.4%TTM4.4%+6.0%
TTM4.4%YOY-18.9%+23.3%
TTM4.4%5Y-16.2%+20.6%
5Y-16.2%10Y-14.4%-1.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ10.4%-14.8%+25.2%
TTM4.4%-15.2%+19.6%
YOY-18.9%-15.1%-3.8%
3Y-15.9%-17.6%+1.7%
5Y-16.2%-18.1%+1.9%
10Y-14.4%-20.1%+5.7%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Sarepta Therapeutics Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Sarepta is operatingΒ .

  • Measures how much profit Sarepta makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Sarepta to theΒ Biotechnology industry mean.
  • An Operating Margin of 0.0%Β means the company generated €0.00 Β for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Sarepta Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-13.6%+13.6%
TTM-5Y-43.1%+43.1%
5Y-43.1%10Y-100.7%+57.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--176.2%+176.2%
TTM--282.8%+282.8%
YOY-13.6%-211.1%+197.5%
3Y-23.5%-249.1%+225.6%
5Y-43.1%-360.9%+317.8%
10Y-100.7%-476.2%+375.5%
4.3.2.2. Operating Ratio

Measures how efficient Sarepta is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 0.96 means that the operating costs are €0.96 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Sarepta Therapeutics Inc:

  • The MRQ is 0.955. The company is less efficient in keeping operating costs low.
  • The TTM is 1.067. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ0.955TTM1.067-0.111
TTM1.067YOY1.387-0.320
TTM1.0675Y1.630-0.564
5Y1.63010Y1.982-0.351
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9552.181-1.226
TTM1.0673.063-1.996
YOY1.3873.051-1.664
3Y1.3933.660-2.267
5Y1.6304.854-3.224
10Y1.9826.545-4.563
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Sarepta Therapeutics Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Sarepta is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 4.20Β means the company has €4.20 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Sarepta Therapeutics Inc:

  • The MRQ is 4.201. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.997. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.201TTM3.997+0.204
TTM3.997YOY4.744-0.748
TTM3.9975Y5.203-1.206
5Y5.20310Y6.653-1.450
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.2013.588+0.613
TTM3.9973.930+0.067
YOY4.7444.298+0.446
3Y4.4614.804-0.343
5Y5.2035.817-0.614
10Y6.6536.197+0.456
4.4.3.2. Quick Ratio

Measures if Sarepta is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Sarepta to theΒ Biotechnology industry mean.
  • A Quick Ratio of 1.17Β means the company can pay off €1.17 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Sarepta Therapeutics Inc:

  • The MRQ is 1.167. The company is just able to pay all its short-term debts with the most liquid assets.
  • The TTM is 1.878. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.167TTM1.878-0.711
TTM1.878YOY2.712-0.835
TTM1.8785Y1.759+0.119
5Y1.75910Y2.433-0.674
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1672.768-1.601
TTM1.8783.419-1.541
YOY2.7124.136-1.424
3Y2.2524.675-2.423
5Y1.7595.993-4.234
10Y2.4336.549-4.116
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Sarepta Therapeutics Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of SareptaΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Sarepta to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.61Β means that Sarepta assets areΒ financed with 61.5% credit (debt) and the remaining percentage (100% - 61.5%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Sarepta Therapeutics Inc:

  • The MRQ is 0.615. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.666. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.615TTM0.666-0.051
TTM0.666YOY0.755-0.090
TTM0.6665Y0.737-0.071
5Y0.73710Y0.579+0.158
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6150.342+0.273
TTM0.6660.342+0.324
YOY0.7550.331+0.424
3Y0.7420.330+0.412
5Y0.7370.359+0.378
10Y0.5790.382+0.197
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Sarepta is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Sarepta to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 159.4% means that company has €1.59 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Sarepta Therapeutics Inc:

  • The MRQ is 1.594. The company is just able to pay all its debts with equity.
  • The TTM is 2.019. The company is just not able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ1.594TTM2.019-0.425
TTM2.019YOY3.094-1.075
TTM2.0195Y3.194-1.175
5Y3.19410Y2.158+1.036
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.5940.408+1.186
TTM2.0190.427+1.592
YOY3.0940.409+2.685
3Y3.3000.430+2.870
5Y3.1940.447+2.747
10Y2.1580.497+1.661
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every €1 in earnings Sarepta generates.

  • Above 15 is considered overpriced butΒ always compareΒ Sarepta to theΒ Biotechnology industry mean.
  • A PE ratio of 20.11 means the investor is paying €20.11Β for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Sarepta Therapeutics Inc:

  • The EOD is 5.689. Based on the earnings, the company is cheap. +2
  • The MRQ is 20.112. Based on the earnings, the company is fair priced.
  • The TTM is 207.576. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD5.689MRQ20.112-14.423
MRQ20.112TTM207.576-187.464
TTM207.576YOY-37.621+245.197
TTM207.5765Y15.290+192.286
5Y15.29010Y-0.154+15.444
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD5.689-1.711+7.400
MRQ20.112-2.407+22.519
TTM207.576-2.998+210.574
YOY-37.621-3.336-34.285
3Y50.903-4.009+54.912
5Y15.290-6.310+21.600
10Y-0.154-6.909+6.755
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Sarepta Therapeutics Inc:

  • The EOD is 16.768. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The MRQ is 59.277. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The TTM is -66.441. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD16.768MRQ59.277-42.509
MRQ59.277TTM-66.441+125.717
TTM-66.441YOY-22.389-44.051
TTM-66.4415Y-32.126-34.314
5Y-32.12610Y-19.470-12.656
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD16.768-2.379+19.147
MRQ59.277-3.217+62.494
TTM-66.441-3.893-62.548
YOY-22.389-4.283-18.106
3Y-39.538-5.416-34.122
5Y-32.126-8.278-23.848
10Y-19.470-9.340-10.130
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Sarepta is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 8.38 means the investor is paying €8.38Β for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Sarepta Therapeutics Inc:

  • The EOD is 2.369. Based on the equity, the company is underpriced. +1
  • The MRQ is 8.375. Based on the equity, the company is overpriced. -1
  • The TTM is 11.798. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD2.369MRQ8.375-6.006
MRQ8.375TTM11.798-3.423
TTM11.798YOY15.671-3.873
TTM11.7985Y15.336-3.538
5Y15.33610Y13.594+1.742
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.3691.696+0.673
MRQ8.3752.127+6.248
TTM11.7982.375+9.423
YOY15.6712.480+13.191
3Y16.0372.757+13.280
5Y15.3363.702+11.634
10Y13.5944.299+9.295
4.6.2. Total Gains per Share

2.4. Latest News of Sarepta Therapeutics Inc

Does Sarepta Therapeutics Inc still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Sarepta Therapeutics Inc to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-05-04
12:46
Oppenheimer Predicts Up to ~840% Surge for These 2 β€˜Strong Buy’ StocksRead
2025-04-18
19:38
Exploring 3 High Growth Tech Stocks In The US MarketRead
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets3,963,173
Total Liabilities2,435,431
Total Stockholder Equity1,527,742
 As reported
Total Liabilities 2,435,431
Total Stockholder Equity+ 1,527,742
Total Assets = 3,963,173

Assets

Total Assets3,963,173
Total Current Assets3,073,463
Long-term Assets889,710
Total Current Assets
Cash And Cash Equivalents 1,103,010
Short-term Investments 251,782
Net Receivables 601,988
Inventory 749,960
Other Current Assets 9,214
Total Current Assets  (as reported)3,073,463
Total Current Assets  (calculated)2,715,954
+/- 357,509
Long-term Assets
Property Plant Equipment 488,646
Long Term Investments 136,873
Intangible Assets 26,887
Long-term Assets Other 206,959
Long-term Assets  (as reported)889,710
Long-term Assets  (calculated)859,365
+/- 30,345

Liabilities & Shareholders' Equity

Total Current Liabilities731,684
Long-term Liabilities1,703,747
Total Stockholder Equity1,527,742
Total Current Liabilities
Accounts payable 214,442
Total Current Liabilities  (as reported)731,684
Total Current Liabilities  (calculated)214,442
+/- 517,242
Long-term Liabilities
Long term Debt 1,137,124
Capital Lease Obligations Min Short Term Debt205,946
Long-term Liabilities Other 49,150
Long-term Liabilities  (as reported)1,703,747
Long-term Liabilities  (calculated)1,392,220
+/- 311,527
Total Stockholder Equity
Total Stockholder Equity (as reported)1,527,742
Total Stockholder Equity (calculated)0
+/- 1,527,742
Other
Capital Stock10
Common Stock Shares Outstanding 96,900
Net Debt 34,114
Net Invested Capital 2,664,866
Net Working Capital 2,341,779
Property Plant and Equipment Gross 722,791



6.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-31
> Total Assets 
424,104
511,533
450,139
800,281
1,307,964
1,300,283
1,247,160
1,182,906
1,642,075
1,963,895
1,747,753
1,702,470
1,822,822
2,947,388
2,883,043
2,780,664
2,984,718
2,765,233
2,759,073
2,662,218
3,147,974
3,056,154
2,996,853
3,156,149
3,128,366
3,059,786
3,125,890
3,109,707
3,264,576
3,224,385
3,424,257
3,599,934
3,963,173
3,963,1733,599,9343,424,2573,224,3853,264,5763,109,7073,125,8903,059,7863,128,3663,156,1492,996,8533,056,1543,147,9742,662,2182,759,0732,765,2332,984,7182,780,6642,883,0432,947,3881,822,8221,702,4701,747,7531,963,8951,642,0751,182,9061,247,1601,300,2831,307,964800,281450,139511,533424,104
   > Total Current Assets 
373,476
457,307
390,585
735,608
1,228,644
1,219,417
1,139,244
1,012,077
1,426,183
1,671,423
1,427,418
1,362,299
1,468,913
2,547,348
2,459,421
2,322,673
2,485,196
2,271,350
2,265,217
2,185,310
2,604,099
2,530,947
2,469,300
2,625,929
2,557,861
2,488,377
2,472,614
2,450,849
2,579,331
2,464,865
2,683,636
2,685,369
3,073,463
3,073,4632,685,3692,683,6362,464,8652,579,3312,450,8492,472,6142,488,3772,557,8612,625,9292,469,3002,530,9472,604,0992,185,3102,265,2172,271,3502,485,1962,322,6732,459,4212,547,3481,468,9131,362,2991,427,4181,671,4231,426,1831,012,0771,139,2441,219,4171,228,644735,608390,585457,307373,476
       Cash And Cash Equivalents 
133,115
274,723
168,348
617,630
599,691
557,234
410,375
209,702
370,829
732,190
808,591
724,829
835,080
1,764,212
1,639,959
1,474,637
1,502,648
1,481,836
1,697,275
1,599,113
2,115,869
1,233,877
868,565
1,038,624
966,777
871,668
851,929
541,932
428,430
427,290
383,622
197,855
1,103,010
1,103,010197,855383,622427,290428,430541,932851,929871,668966,7771,038,624868,5651,233,8772,115,8691,599,1131,697,2751,481,8361,502,6481,474,6371,639,9591,764,212835,080724,829808,591732,190370,829209,702410,375557,234599,691617,630168,348274,723133,115
       Short-term Investments 
195,425
115,590
132,598
0
479,369
491,757
538,769
583,158
803,083
612,018
294,478
324,063
289,668
406,940
421,349
341,467
435,923
255,997
30,000
0
0
779,548
1,059,454
1,033,860
1,022,597
1,010,429
1,008,786
1,191,610
1,247,820
963,453
1,076,852
1,000,534
251,782
251,7821,000,5341,076,852963,4531,247,8201,191,6101,008,7861,010,4291,022,5971,033,8601,059,454779,5480030,000255,997435,923341,467421,349406,940289,668324,063294,478612,018803,083583,158538,769491,757479,3690132,598115,590195,425
       Net Receivables 
5,228
12,278
17,791
24,751
29,468
39,848
53,394
59,388
64,436
49,718
56,189
67,260
93,938
109,934
107,087
124,886
138,583
136,367
148,264
181,558
171,637
197,201
230,275
223,450
259,697
288,076
267,158
318,855
400,327
378,806
359,997
434,524
601,988
601,988434,524359,997378,806400,327318,855267,158288,076259,697223,450230,275197,201171,637181,558148,264136,367138,583124,886107,087109,93493,93867,26056,18949,71864,43659,38853,39439,84829,46824,75117,79112,2785,228
       Inventory 
12,813
30,445
41,754
64,693
83,605
99,375
104,126
115,816
125,445
140,467
156,569
166,360
171,379
173,168
179,650
220,118
231,961
240,333
268,756
288,469
186,212
198,997
208,095
221,192
203,968
202,675
226,876
244,011
322,859
373,530
485,795
565,924
749,960
749,960565,924485,795373,530322,859244,011226,876202,675203,968221,192208,095198,997186,212288,469268,756240,333231,961220,118179,650173,168171,379166,360156,569140,467125,445115,816104,12699,37583,60564,69341,75430,44512,813
       Other Current Assets 
26,895
24,271
23,704
20,922
22,414
17,449
17,206
23,339
42,514
4,949
5,927
5,109
61,639
73,060
91,548
132,396
143,434
123,958
93,601
91,552
100,898
93,815
79,307
83,411
75,179
86,799
90,466
13,669
12,478
8,076
8,242
7,852
9,214
9,2147,8528,2428,07612,47813,66990,46686,79975,17983,41179,30793,815100,89891,55293,601123,958143,434132,39691,54873,06061,6395,1095,9274,94942,51423,33917,20617,44922,41420,92223,70424,27126,895
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
292,472
320,335
340,171
353,909
400,040
423,622
457,991
499,522
493,883
493,856
476,908
543,875
525,207
527,553
530,220
570,505
571,409
653,276
658,858
685,245
759,520
740,621
914,565
889,710
889,710914,565740,621759,520685,245658,858653,276571,409570,505530,220527,553525,207543,875476,908493,856493,883499,522457,991423,622400,040353,909340,171320,335292,472000000000
       Property Plant Equipment 
37,801
38,412
39,393
38,872
43,156
53,927
57,624
76,841
97,024
147,378
156,650
159,025
167,553
200,422
227,537
242,800
282,191
268,175
276,198
271,912
236,687
233,230
230,291
224,039
244,991
244,878
323,602
345,821
357,106
375,571
400,201
446,686
488,646
488,646446,686400,201375,571357,106345,821323,602244,878244,991224,039230,291233,230236,687271,912276,198268,175282,191242,800227,537200,422167,553159,025156,650147,37897,02476,84157,62453,92743,15638,87239,39338,41237,801
       Long Term Investments 
0
0
0
0
9,980
0
0
30,000
31,739
32,359
32,154
31,834
31,937
33,697
33,344
32,769
38,799
40,640
39,971
35,288
34,892
33,394
33,234
33,244
31,321
31,000
31,000
7,500
6,527
41,376
7,606
186,493
136,873
136,873186,4937,60641,3766,5277,50031,00031,00031,32133,24433,23433,39434,89235,28839,97140,64038,79932,76933,34433,69731,93731,83432,15432,35931,73930,000009,9800000
       Intangible Assets 
8,076
7,684
7,795
14,029
14,355
14,473
14,857
15,324
11,574
11,781
11,825
11,975
12,497
12,813
13,105
13,344
13,628
0
0
0
14,239
0
0
0
7,578
0
0
0
29,620
0
0
0
26,887
26,88700029,6200007,57800014,23900013,62813,34413,10512,81312,49711,97511,82511,78111,57415,32414,85714,47314,35514,0297,7957,6848,076
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
8,926
11,797
11,660
11,799
11,981
11,603
12,198
12,984
12,407
12,731
12,786
143,285
134,812
145,044
159,685
187,056
191,737
194,981
199,027
212,322
226,464
223,414
221,782
206,959
206,959221,782223,414226,464212,322199,027194,981191,737187,056159,685145,044134,812143,28512,78612,73112,40712,98412,19811,60311,98111,79911,66011,7978,926000000000
> Total Liabilities 
87,413
82,391
72,367
103,125
518,747
523,523
548,113
543,058
609,799
615,331
648,586
707,266
1,004,635
1,802,560
1,840,177
1,888,617
2,222,959
2,229,788
2,273,965
2,192,690
2,219,965
2,199,268
2,270,396
2,725,309
2,743,416
2,347,037
2,384,479
2,345,350
2,405,239
2,263,193
2,347,188
2,378,863
2,435,431
2,435,4312,378,8632,347,1882,263,1932,405,2392,345,3502,384,4792,347,0372,743,4162,725,3092,270,3962,199,2682,219,9652,192,6902,273,9652,229,7882,222,9591,888,6171,840,1771,802,5601,004,635707,266648,586615,331609,799543,058548,113523,523518,747103,12572,36782,39187,413
   > Total Current Liabilities 
75,422
74,629
65,960
70,470
88,332
91,196
104,687
114,393
173,690
137,366
162,089
215,856
264,767
306,429
354,896
378,388
416,026
364,736
425,022
373,443
452,733
454,962
545,566
602,916
619,604
536,884
498,654
450,743
653,659
608,709
688,490
699,489
731,684
731,684699,489688,490608,709653,659450,743498,654536,884619,604602,916545,566454,962452,733373,443425,022364,736416,026378,388354,896306,429264,767215,856162,089137,366173,690114,393104,68791,19688,33270,47065,96074,62975,422
       Short-term Debt 
10,108
11,346
11,217
4,732
6,175
3,446
9,514
0
0
6,762
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000006,762009,5143,4466,1754,73211,21711,34610,108
       Short Long Term Debt 
10,108
11,346
11,217
4,732
6,175
3,446
9,514
0
0
6,762
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
105,483
105,586
91,505
91,595
0
091,59591,505105,586105,4830000000000000000006,762009,5143,4466,1754,73211,21711,34610,108
       Accounts payable 
60,706
58,603
10,921
5,317
8,467
17,379
17,382
20,408
33,829
26,499
44,045
81,946
68,094
26,595
91,660
74,528
111,090
76,651
76,681
44,163
76,741
54,007
56,207
118,461
95,875
106,710
109,796
87,948
164,918
91,536
107,417
118,774
214,442
214,442118,774107,41791,536164,91887,948109,796106,71095,875118,46156,20754,00776,74144,16376,68176,651111,09074,52891,66026,59568,09481,94644,04526,49933,82920,40817,38217,3798,4675,31710,92158,60360,706
       Other Current Liabilities 
4,608
4,680
9,346
12,257
15,478
24,555
25,692
30,697
39,801
6,762
7,413
8,944
57,549
148,502
145,490
148,560
141,580
151,710
141,077
154,243
154,278
160,480
160,473
163,149
172,568
159,474
152,255
17,951
0
16,270
17,128
17,289
0
017,28917,12816,270017,951152,255159,474172,568163,149160,473160,480154,278154,243141,077151,710141,580148,560145,490148,50257,5498,9447,4136,76239,80130,69725,69224,55515,47812,2579,3464,6804,608
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
477,965
486,497
491,410
739,868
1,496,131
1,485,281
1,510,229
1,806,933
1,865,052
1,848,943
1,819,247
1,767,232
1,744,306
1,724,830
2,122,393
2,123,812
1,810,153
1,885,825
1,894,607
1,751,580
1,654,484
1,658,698
1,679,374
1,703,747
1,703,7471,679,3741,658,6981,654,4841,751,5801,894,6071,885,8251,810,1532,123,8122,122,3931,724,8301,744,3061,767,2321,819,2471,848,9431,865,0521,806,9331,510,2291,485,2811,496,131739,868491,410486,497477,965000000000
       Capital Lease Obligations 
0
0
0
0
0
0
0
0
0
52,165
50,209
49,741
47,720
65,263
72,401
68,229
80,367
60,675
65,285
63,428
41,512
38,620
39,368
35,229
73,067
53,931
129,170
134,752
158,810
140,102
143,601
170,009
205,946
205,946170,009143,601140,102158,810134,752129,17053,93173,06735,22939,36838,62041,51263,42865,28560,67580,36768,22972,40165,26347,72049,74150,20952,165000000000
       Other Liabilities 
0
5,419
6,407
6,105
5,539
4,962
13,501
13,219
15,555
48
5,248
5,248
10,248
742,915
718,724
741,530
734,073
713,267
690,673
660,907
628,844
606,839
584,589
544,394
521,942
521,938
0
0
0
0
0
0
0
0000000521,938521,942544,394584,589606,839628,844660,907690,673713,267734,073741,530718,724742,91510,2485,2485,2484815,55513,21913,5014,9625,5396,1056,4075,4190
> Total Stockholder Equity
336,691
429,142
377,772
697,156
789,217
776,760
699,047
639,848
1,032,276
1,348,564
1,099,167
995,204
818,187
1,144,828
1,042,866
892,047
761,759
535,445
485,108
469,528
928,009
856,886
726,457
430,840
384,950
712,749
741,411
764,357
859,337
961,192
1,077,069
1,221,071
1,527,742
1,527,7421,221,0711,077,069961,192859,337764,357741,411712,749384,950430,840726,457856,886928,009469,528485,108535,445761,759892,0471,042,8661,144,828818,187995,2041,099,1671,348,5641,032,276639,848699,047776,760789,217697,156377,772429,142336,691
   Common Stock
5
5
6
6
6
7
7
7
7
7
7
7
8
8
8
8
8
8
8
8
9
9
9
9
9
9
0
0
0
0
0
0
0
000000099999988888888777777766655
   Retained Earnings Total Equity000000000000000000000000000000000
   Accumulated Other Comprehensive Income 000000000000000000000000000000000
   Capital Surplus 000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000
   Other Stockholders Equity 
-120
-55
-38
-12
-379
-643
-361
8
-99
19
82
75
50
624
6
-6
3
-3
2
-20
-20
-306
-2,485
-3,205
-1,664
-419
0
0
0
0
0
0
0
0000000-419-1,664-3,205-2,485-306-20-202-33-6662450758219-998-361-643-379-12-38-55-120



6.3. Balance Sheets

Currency in USD. All numbers in thousands.




6.4. Cash Flows

Currency in USD. All numbers in thousands.




6.5. Income Statements

Currency in USD. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue1,901,979
Cost of Revenue-319,099
Gross Profit1,582,8801,582,880
 
Operating Income (+$)
Gross Profit1,582,880
Operating Expense-1,683,898
Operating Income218,081-101,018
 
Operating Expense (+$)
Research Development804,522
Selling General Administrative557,872
Selling And Marketing Expenses-
Operating Expense1,683,8981,362,394
 
Net Interest Income (+$)
Interest Income71,767
Interest Expense-18,391
Other Finance Cost-0
Net Interest Income53,376
 
Pretax Income (+$)
Operating Income218,081
Net Interest Income53,376
Other Non-Operating Income Expenses-
Income Before Tax (EBT)260,774228,764
EBIT - interestExpense = -18,391
235,239
253,630
Interest Expense18,391
Earnings Before Interest and Taxes (EBIT)-279,165
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax260,774
Tax Provision-25,535
Net Income From Continuing Ops235,239235,239
Net Income235,239
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-10,683-53,376
 

Technical Analysis of Sarepta
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Sarepta. The general trend of Sarepta is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Sarepta's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Sarepta Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Sarepta Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 43.43 < 80.16 < 81.78.

The bearish price targets are: .

Know someone who trades $AB3A? Share this with them.πŸ‘‡

Sarepta Therapeutics Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Sarepta Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Sarepta Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Sarepta Therapeutics Inc. The current macd is -6.33109271.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Sarepta price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Sarepta. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Sarepta price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Sarepta Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartSarepta Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Sarepta Therapeutics Inc. The current adx is 29.58.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Sarepta shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
Sarepta Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Sarepta Therapeutics Inc. The current sar is 55.82.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Sarepta Therapeutics Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Sarepta Therapeutics Inc. The current rsi is 24.92. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 1/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
Sarepta Therapeutics Inc Daily Relative Strength Index (RSI) ChartSarepta Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Sarepta Therapeutics Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Sarepta price going down in the near term. -2
  • Trending up: The STOCH %K is trending up. +1
Sarepta Therapeutics Inc Daily Stochastic Oscillator ChartSarepta Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Sarepta Therapeutics Inc. The current cci is -224.6512869.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Sarepta Therapeutics Inc Daily Commodity Channel Index (CCI) ChartSarepta Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Sarepta Therapeutics Inc. The current cmo is -56.54592531.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Sarepta Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartSarepta Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Sarepta Therapeutics Inc. The current willr is -96.64147775.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Sarepta Therapeutics Inc Daily Williams %R ChartSarepta Therapeutics Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Sarepta Therapeutics Inc.

Sarepta Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Sarepta Therapeutics Inc. The current atr is 3.59377312.

Sarepta Therapeutics Inc Daily Average True Range (ATR) ChartSarepta Therapeutics Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Sarepta Therapeutics Inc. The current obv is -12,940.

Sarepta Therapeutics Inc Daily On-Balance Volume (OBV) ChartSarepta Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Sarepta Therapeutics Inc. The current mfi is 21.74.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Sarepta Therapeutics Inc Daily Money Flow Index (MFI) ChartSarepta Therapeutics Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Sarepta Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-12-11 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-13 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-12-16 00:00:00CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-17 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-18 00:00:00WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-19 00:00:00SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-20 00:00:00CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-12-27 00:00:00CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-30 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-01-03 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-06 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-01-08 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-01-09 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-13 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-01-14 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-16 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-01-17 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-01-20 00:00:00MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-01-22 00:00:00CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-01-24 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-27 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-01-28 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-30 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-04 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-05 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-02-06 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-07 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-11 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-12 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-19 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-20 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-24 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-02-26 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-27 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-28 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-03 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-04 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-06 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-07 00:00:00CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-10 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-11 00:00:00BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-12 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-13 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-17 00:00:00ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-18 00:00:00BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-03-20 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-03-21 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-25 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-26 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-31 00:00:00CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-01 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-02 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-03 00:00:00ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-04 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-07 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-08 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-09 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-10 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-11 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-04-15 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-22 00:00:00SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-04-23 00:00:00RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-25 00:00:00CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-28 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-29 00:00:00CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-30 00:00:00CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-02 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-05 00:00:00CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-05-07 00:00:00SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-08 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.

6.3. Candlestick Patterns

Sarepta Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Sarepta Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5024.918
Ma 20Greater thanMa 5048.069
Ma 50Greater thanMa 10068.140
Ma 100Greater thanMa 20090.752
OpenGreater thanClose33.200
Total1/5 (20.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Sarepta with someone you think should read this too:
  • Are you bullish or bearish on Sarepta? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Sarepta? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Sarepta Therapeutics Inc

I send you an email if I find something interesting about Sarepta Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Sarepta Therapeutics Inc.

Receive notifications about Sarepta Therapeutics Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.